AI-Designed TB treatment aims for 99.5% cure rate
NCT ID NCT07467252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests whether an AI-optimized combination of pyrazinamide and hydroxychloroquine works better than the standard four-drug RIPE regimen for newly diagnosed drug-sensitive pulmonary tuberculosis. Two hundred adults will receive either the new AI-personalized treatment or standard care for 6 months, with follow-up for another 6 months. The study aims to see if the new combo clears the bacteria faster and causes fewer liver side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pyrazinamide and hydroxychloroquine
- What this could lead to
- If successful, this could lead to a more effective and safer treatment for tuberculosis, potentially curing more patients with fewer side effects.
- What could go wrong
- This is a Phase II trial with only 200 participants, so results may not apply to everyone. The AI-optimized dosing is new and unproven in humans, and hydroxychloroquine has known risks like heart rhythm problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Riyadh First Health Cluster, Ministry of Health
Riyadh, Riyadh Region, 11176, Saudi Arabia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new patient cohort unlock the secrets of TB treatment success?
- Shorter TB treatment: a 4-Month regimen put to the test
- Lung damage after TB: a new study tests whether rehabilitation can restore breathing and quality of life
- Can a more powerful antibiotic clear TB faster? a trial puts rifapentine to the test.
- Could a simple screening strategy uncover hidden TB in COPD patients?
- Talking it out: could counseling be the key to beating TB?